EPHB2 and cancer: Recent pan-cancer studies reveal that molecular alterations like PLIN3/EPHB2 dysregulation and hypoxia-related signatures consistently promote M2 macrophage infiltration and immunosuppression, correlating with adverse outcomes across malignancies (22).